Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PRRSF$0.04+0.00(+10.13%)Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement[6:35:00 PM ET]OTAI$10.11+0.00(+0.05%)Spider Digital Technology Ltd. and Starlink AI Acquisition Corporation Announce Definitive Business Combination Agreement[6:30:00 PM ET]REVVF$0.170.00(0.00%)Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario[6:30:00 PM ET]CTSH$65.00+2.48(+3.97%)Cognizant setzt mehr als 25.000 Fachkräfte für die Umsetzung von OpenAI-Lösungen ein, während Unternehmen bahnbrechende KI-Technologien in die Produktion überführen Cognizant (Nasdaq: CTSH) gab heute die Gründung seiner „OpenAI Frontier Capability Group" bekannt, in der mehr als 25.000 Fachkräfte zusammenkommen,...[6:17:00 PM ET]INO$2.07+1.30(+168.20%)INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...[6:01:00 PM ET]KVUE$19.31-0.25(-1.28%)Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on...[5:51:00 PM ET]ACET$3.42-0.16(-4.47%)Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)[5:38:00 PM ET]BKOR$31.900.00(0.00%)Oak Ridge Financial Services, Inc. Announces Third Quarter and Nine Months Ended September 30, 2026 Results and Quarterly Cash Dividend of $0.16 Per Common Share[5:32:47 PM ET]BHAVU$10.170.00(0.00%)BHAV Acquisition Corp II Announces Closing of $100 Million Initial Public Offering[5:30:00 PM ET]SABA$7.62-0.03(-0.39%)SABA Announces Notification of Sources of Distributions[5:30:00 PM ET]BRW$6.00+0.01(+0.17%)BRW Announces Notification of Sources of Distributions[5:30:00 PM ET]MUEL$416.00-6.00(-1.42%)Paul Mueller Company Announces Its Third Quarter Earnings of 2026[5:28:01 PM ET]NBRKF$0.13-0.00(-2.00%)New Break Announces $550,000 Non-Brokered Private Placement Offering of Flow-Through Shares[5:23:00 PM ET]FUJIY$10.98+0.06(+0.55%)Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape[5:18:00 PM ET]

ACET · NASDAQ

Adicet Bio, Inc.

$3.41 -0.20 (-5.54%)

Company overview

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company engineers gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune responses, and improve persistence for durable activity in patients. Its lead pipeline product, ADI-001, is in a Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company is also developing ADI-002, which is undergoing preclinical studies for various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$31.9M
Employees
152
Headquarters
Boston, MA
Website
adicetbio.com
CEO
Chen Schor
Listed
January 26, 2018
P/E
-0.23
Dividend yield
0.01%

Company financials

Revenue
$0.00
Gross profit
-$1.3M
Operating income
-$114M
EBITDA
-$104M
Net income
-$109M
EPS
-$14.90
Total assets
$169M
Total debt
$13.9M
Earnings yield
-436.95%

Price chart

3.305.036.778.5010.23
ACET 1D NASDAQ O3.83H3.86L3.56C3.58-0.23 (-6.04%)Vol176.21K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ACETAdicet Bio, Inc. Press release Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
ACETAdicet Bio, Inc. Press release Adicet Bio to Participate in Upcoming Investor Conferences Business Wire
ACETAdicet Bio, Inc. Stock news Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months MarketBeat
ACETAdicet Bio, Inc. Press release Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
ACETAdicet Bio, Inc. Stock news Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript Seeking Alpha
ACETAdicet Bio, Inc. Stock news Is Tenet Healthcare (THC) Outperforming Other Medical Stocks This Year? Zacks Investment Research
ACETAdicet Bio, Inc. Press release Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis Business Wire
GTLL Stock news Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Benzinga
ACETAdicet Bio, Inc. Press release Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis Business Wire
ACETAdicet Bio, Inc. Stock news Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? Zacks Investment Research
ACETAdicet Bio, Inc. Stock news Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? Zacks Investment Research
ACETAdicet Bio, Inc. Stock news Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference Business Wire
ACETAdicet Bio, Inc. Stock news Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference GuruFocus
ACETAdicet Bio, Inc. Press release Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Business Wire
ACETAdicet Bio, Inc. Press release Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
ACETAdicet Bio, Inc. Press release Adicet Bio Announces FDA Clearance of IND Application for ADI-212 Business Wire
ACETAdicet Bio, Inc. Stock news Here's Why You Should Add ACET Stock to Your Portfolio Now Zacks Investment Research
ACETAdicet Bio, Inc. Stock news Are Medical Stocks Lagging Adicet Bio (ACET) This Year? Zacks Investment Research
ACETAdicet Bio, Inc. Stock news Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet Zacks Investment Research
ACETAdicet Bio, Inc. Stock news Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy MarketBeat
See more
FAQ

Questions about Adicet Bio, Inc.

What does Adicet Bio, Inc. do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company engineers gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune responses, and improve persistence for durable activity in patients. Its lead pipeline product, ADI-001, is in a Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company is also developing ADI-002, which is undergoing preclinical studies for various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
What is ACET's market cap?
Adicet Bio, Inc. (ACET) is a listed stock with a live quote. The latest market cap on this page is $31.9M.
Where is Adicet Bio, Inc. headquartered?
Adicet Bio, Inc. is headquartered in Boston, MA.
How do I get ACET news from the API?
Call GET /v1/news?tickers=ACET. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ACET news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ACET, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ACET price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs